$MESO

Mesoblast (MESO) shares rose about 9.5% after the company said it completed patient treatment in the MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain from degenerative disc disease. The trial enrolled 350 patients versus 300 planned. The primary endpoint targets durable pain reduction at 12 months, with FDA RMAT designation and a BLA submission targeted for Q3 2027.

Mesoblast Limited (NASDAQ:MESO) shares rose 9.5% after the company said it completed patient treatment in its Phase 3 MSB-DR004 trial of rexlemestrocel-L for chronic low back pain. The study treated 350 patients randomized to rexlemestrocel-L or sham injection. Top-line results are expected mid-2027 after 12-month follow-up.

Mesoblast Limited (Nasdaq:MESO) said it reached its target of at least 300 treated patients in the MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. The primary endpoint compares pain reduction at 12 months vs sham. Top-line results are expected mid-2027.

Australia’s S&P/ASX 200 fell 0.41% to 8,770.2 by midday Monday as Middle East tensions and IMF warnings weighed on sentiment. The IMF cut Australia’s 2026 growth forecast to 1.9% and flagged inflation near 4%. Coles slid on a reported Greencross deal; Santos and Woodside were softer; Mesoblast was upgraded to buy with a $4.45 target.

ASX futures pointed to a 0.49% rise at the open after Wall Street ended higher, supported by AI and chip stocks. The ASX 200 rose 0.5% on Friday to 8,806, led by mining and financials. Telstra fell 1.6%, WiseTech 1.8%, while Mesoblast rose 6% on US$115m FY2026 revenue. Geopolitical Iran tensions and oil moves weighed on sentiment.

Mesoblast Limited (Nasdaq:MESO) reported Ryoncil net revenue of $36 million for the quarter ended June 30, 2026, and $115 million for the full fiscal year. The company said revenues exceeded initial projections and expects continued growth, citing uptake in major U.S. pediatric centers. Results are preliminary pending audit.

Mesoblast (MESO) stock is gaining attention due to strong Q1 2026 sales of Ryoncil, reaching $30.3 million and nearing $100 million in cumulative revenue. The FDA's Investigational New Drug clearance for Ryoncil in Duchenne muscular dystrophy is seen as a significant breakthrough, paving the way for a registrational trial. Insider purchases and institutional activity also reflect growing confidence, with Wall Street analysts issuing "Buy" ratings.

Mesoblast has received FDA Investigational New Drug (IND) clearance to directly proceed with a registrational trial for Ryoncil in Duchenne muscular dystrophy (DMD). The trial will enroll 76 patients aged 5-9, with time-to-stand at nine months as the primary endpoint. This builds on Ryoncil's existing pediatric safety profile, preclinical efficacy in DMD models, and an FDA-approved manufacturing process.

Shares of Challenger, Lotus Resources, Mesoblast, and Wildcat Resources are all falling today despite a general market gain. Challenger's shares are down despite a new partnership with Bank of Queensland, while Lotus Resources is down due to a production delay at its uranium mine caused by fire damage. Mesoblast's shares are falling after a sales update for its Ryoncil treatment may have disappointed investors, and Wildcat Resources saw a decline despite a drilling update showing an extension of mineralisation at one of its projects.

Mesoblast (NASDAQ:MESO) shares have fallen below their 50-day moving average, trading at $14.36 against a moving average of $16.63. The company has a "Moderate Buy" consensus rating from analysts, despite a recent "sell" rating from Weiss Ratings. Mesoblast reported Q4 EPS of -$0.16 and revenue of $25.67 million, with institutional investors holding a small percentage of the stock.